


CLAIMS


1. A compound having formula (I), or a pharmaceutically acceptable salt, or a stereoisomer thereof:



wherein:

W' is H;

- W is independently selected from: -O-CH₂CH(OH)(CH₂OH), -NH-(CH₂)₃₋₄-OH,
 10 -NH-(CH₂)₁₋₂-CH(CH₃)OH, -NH-(CH₂)₁₋₂-C(CH₃)₂OH, -O-(CH₂)₁₋₂-(pyrazolyl),
 -NH-(CH₂)₁₋₂-(pyrazolyl), -NH-(CH₂)₁₋₂-(pyrimidinyl), -NH-(CH₂)₁₋₂-(pyridazinyl),




R³ is independently or ; and
 R⁴ is independently H or F.

2. A compound according to claim 1, or a pharmaceutically acceptable salt, or a stereoisomer thereof, wherein:

W' is H;

- W is independently selected from: -O-CH₂CH(OH)(CH₂OH), -NH-(CH₂)₃₋₄-OH,
 20 -NH-(CH₂)₁₋₂-CH(CH₃)OH, -NH-(CH₂)₁₋₂-C(CH₃)₂OH, -NH-(CH₂)₁₋₂-(pyrazolyl), and






- W' is H ;

*N[C@H]1CCCC[C@@H]1O


10


- [illegible]



or a pharmaceutically acceptable salt thereof.


5. A compound according to claim 4, wherein the compound is selected from:






or a pharmaceutically acceptable salt thereof.

6. A compound according to claim 4, wherein the compound is selected from:




10 or a pharmaceutically acceptable salt thereof.

7. A compound according to claim 1, wherein the compound is:




or a pharmaceutically acceptable salt thereof.

8. A compound according to claim 1, wherein the compound is:




9. A compound according to claim 1, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

10

10. A compound according to claim 1, wherein the compound is:



11. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt, or a stereoisomer thereof as claimed in any one of claims 1 to 10 and one or more pharmaceutically acceptable excipients.

12. A compound or a pharmaceutically acceptable salt, or a stereoisomer thereof according to anyone of claims 1 to 10, or a pharmaceutical composition according to claim 11, for use in the treatment of cancer.

13. Use of a compound or a pharmaceutically acceptable salt, or a stereoisomer thereof as claimed in any one of claims 1 to 10, or a pharmaceutical composition as claimed in claim 11 in the manufacture of a medicament for the treatment of cancer.

14. The compound or a pharmaceutically acceptable salt, or a stereoisomer thereof or
10 the pharmaceutical composition for use according to claim 12, or the use according to claim 13, wherein the cancer is selected from acute myeloid leukemia, adrenocortical carcinoma, Kaposi sarcoma, lymphoma, anal cancer, appendix cancer, teratoid/rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain cancer, breast cancer, bronchial tumor, carcinoid tumor, cardiac tumor, cervical cancer, chordoma, chronic lymphocytic leukemia, chronic myeloproliferative neoplasm, colon cancer, colorectal cancer, craniopharyngioma, endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, Ewing sarcoma, eye cancer, fallopian tube cancer, gallbladder cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor, germ cell tumor, hairy cell leukemia, head and neck cancer, heart cancer, liver
20 cancer, hypopharyngeal cancer, pancreatic cancer, kidney cancer, laryngeal cancer, chronic myelogenous leukemia, lip and oral cavity cancer, lung cancer, melanoma, Merkel cell carcinoma, mesothelioma, mouth cancer, oral cancer, osteosarcoma, ovarian cancer, penile cancer, pharyngeal cancer, prostate cancer, rectal cancer, salivary gland cancer, skin cancer, small intestine cancer, soft tissue sarcoma, testicular cancer, throat cancer, thyroid cancer, urethral cancer, uterine cancer, vaginal cancer, and vulvar cancer.

15. The compound or a pharmaceutically acceptable salt, or a stereoisomer thereof or the pharmaceutical composition for use according to claim 12 or claim 14, or the use according to claim 13 or claim 14, wherein the cancer is a refractory cancer.

30

16. The compound or a pharmaceutically acceptable salt, or a stereoisomer thereof or the pharmaceutical composition for use according to claim 12, or the use according to

claim 13, wherein the cancer is selected from breast cancer, colon cancer, rectal cancer, colorectal cancer, pancreatic cancer, and prostate cancer.

17. The compound or a pharmaceutically acceptable salt, or a stereoisomer thereof or the pharmaceutical composition for use according to claim 12, or the use according to claim 13, wherein the cancer is selected from hormone receptor positive breast cancer, microsatellite stable colon or rectal cancer, pancreatic cancer and prostate cancer.

18. The compound or a pharmaceutically acceptable salt, or a stereoisomer thereof or
10 the pharmaceutical composition for use according to any one of claims 12, and 14-17 or the use of claims 13-17, wherein the compound or a pharmaceutically acceptable salt, or a stereoisomer thereof or the pharmaceutical composition is to be administered in combination with one or more additional cancer therapies; or one or more additional therapeutic agent.

19. The compound or a pharmaceutically acceptable salt, or a stereoisomer thereof or the pharmaceutical composition for use or the use according to claim 18, wherein the one or more additional cancer therapies comprise surgery, radiotherapy, chemotherapy, toxin therapy, immunotherapy, cryotherapy or gene therapy, or a combination thereof.

20

20. The compound or a pharmaceutically acceptable salt, or a stereoisomer thereof or the pharmaceutical composition for use or the use according to claim 18, wherein the additional cancer therapy or additional therapeutic agent comprises one or more agents selected from cisplatin, carboplatin, mechlorethamine, cyclophosphamide, chlorambucil, ifosfamide, oxaliplatin; azathioprine, mercaptopurine, Vincristine, Vinblastine, Vinorelbine, Vindesine, Taxol, Paclitaxel, Docetaxel; irinotecan, topotecan, amsacrine, etoposide, etoposide phosphate, teniposide, actinomycin, anthracyclines, doxorubicin, daunorubicin, valrubicin, idarubicin, epirubicin, bleomycin, plicamycin, mitomycin, leuprolidine, goserelin, triptorelin, histrelin, bicalutamide, flutamide, nilutamide,
30 Abciximab, Adalimumab, Alemtuzumab, Atlizumab, Basiliximab, Belimumab, Bevacizumab, Brentuximab vedotin, Canakinumab, Cetuximab, Certolizumab pegol, Daclizumab, Denosumab, Eculizumab, Efalizumab, Gemtuzumab, Golimumab,

Ibritumomab tiuxetan, Infliximab, Ipilimumab, Muromonab-CD3, Natalizumab, Ofatumumab, Omalizumab, Palivizumab, Panitumumab, Ranibizumab, Rituximab, Tocilizumab, Tositumomab, Trastuzumab, interleukin-2 (IL-2), indoleamine 2,3-dioxygenase (IDO), IL-10, transforming growth factor- β (TGF β), CD39, CD73 Adenosine-CD39-CD73, and CXCR4-CXCL12.

21. The compound or a pharmaceutically acceptable salt, or a stereoisomer thereof or the pharmaceutical composition for use or the use according to claim 18, wherein the additional cancer therapy or additional therapeutic agent comprises

10 one or more agents selected from nivolumab, pembrolizumab, PDR001, MEDI-0680, cemiplimab, JS001, BGB-A317, INCSHR1210, TSR-042, GLS-010, AM-0001, STI-1110, AGEN2034, MGD013, IBI308, BMS-936559, atezolizumab, durvalumab, avelumab, STI-1014, CX-072, LY3300054, CK-301, urelumab, PF-05082566, MEDI6469, TRX518, varlilumab, CP-870893, BMS-986016, MGA271, lirilumab, IPH2201, emactuzumab, INCB024360, galunisertib, ulocuplumab, BKT140, Bavituximab, CC-90002, bevacizumab, MNRP1685A, ipilimumab, MK-1308, AGEN-1884, and tremelimumab.

22. The compound or a pharmaceutically acceptable salt, or a stereoisomer thereof or
20 the pharmaceutical composition for use or the use according to claim 18, wherein the additional cancer therapy or additional therapeutic agent comprises one or more agents selected from nivolumab, ipilimumab, pembrolizumab, atezolizumab, durvalumab and avelumab.